Kenichi Suda

List of Publications by Citations

Source: https://exaly.com/author-pdf/2798381/kenichi-suda-publications-by-citations.pdf
Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86 papers	2,829 citations	26 h-index	52 g-index
98 ext. papers	3,410 ext. citations	5.3 avg, IF	5.27 L-index

#	Paper	IF	Citations
86	New and emerging targeted treatments in advanced non-small-cell lung cancer. *Lancet, The*, **2016**, 388, 1012-24	40	299
85	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. *Journal of Thoracic Oncology*, **2011**, 6, 1152-61	8.9	211
84	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. *Clinical Cancer Research*, **2010**, 16, 5489-98	12.9	175
83	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. *Cancer and Metastasis Reviews*, **2010**, 29, 49-60	9.6	164
82	Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. *Journal of Thoracic Oncology*, **2009**, 4, 1415-9	8.9	129
81	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. *Clinical Cancer Research*, **2015**, 21, 5305-13	12.9	126
80	EGFR T790M mutation: a double role in lung cancer cell survival?. *Journal of Thoracic Oncology*, **2009**, 4, 1-4	8.9	126
79	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). *Lung Cancer*, **2016**, 98, 69-75	5.9	114
78	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. *Cancer and Metastasis Reviews*, **2012**, 31, 807-14	9.6	110
77	Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. *Lung Cancer*, **2011**, 74, 139-44	5.9	104
76	Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. *Journal of Thoracic Oncology*, **2012**, 7, 1640-4	8.9	94
75	Surgery for NSCLC in the era of personalized medicine. *Nature Reviews Clinical Oncology*, **2013**, 10, 235-44	19.4	75
74	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 2149-57	6.1	73
73	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. *Scientific Reports*, **2015**, 5, 14447	4.9	63
72	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. *Journal of Thoracic Oncology*, **2019**, 14, 1753-1765	8.9	51
71	Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. *Lung Cancer*, **2012**, 76, 292-9	5.9	45
70	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. *International Journal of Cancer*, **2014**, 135, 1002-6	7.5	41

69	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. *Lung Cancer*, **2018**, 126, 72-79	5.9	38
68	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. *Lung Cancer*, **2017**, 104, 85-90	5.9	36
67	Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung Cancer*, **2012**, 78, 207-11	5.9	32
66	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. *Journal of Thoracic Oncology*, **2021**, 16, 1321-1332	8.9	32
65	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. *Lung Cancer*, **2016**, 91, 36-40	5.9	29
64	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. *Cancer Science*, **2016**, 107, 461-8	6.9	29
63	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. *Archives of Toxicology*, **2015**, 89, 1227-40	5.8	28
62	Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. *Journal of Thoracic Oncology*, **2012**, 7, 1078-85	8.9	28
61	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. *Cancer Treatment Reviews*, **2019**, 72, 15-27	14.4	26
60	Successes and limitations of targeted cancer therapy in lung cancer. *Progress in Tumor Research*, **2014**, 41, 62-77		26
59	Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. *Clinical Cancer Research*, **2014**, 20, 3613-22	12.9	26
58	Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. *International Journal of Cancer*, **2016**, 138, 1024-32	7.5	25
57	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. *Expert Review of Anticancer Therapy*, **2017**, 17, 779-786	3.5	24
56	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 2257-2265	6.1	23
55	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. *Lung Cancer*, **2018**, 126, 149-155	5.9	23
54	Early-Stage NSCLC: Advances in Thoracic Oncology 2018. *Journal of Thoracic Oncology*, **2019**, 14, 968-978	8.9	22
53	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. *International Journal of Clinical Oncology*, **2011**, 16, 294-305	4.2	22
52	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. *Lung Cancer*, **2017**, 109, 1-8	5.9	19

51	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. *Journal of Thoracic Oncology*, **2017**, 12, 27-35	8.9	19
50	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. *Journal of Thoracic Oncology*, **2018**, 13, 1496-1507	8.9	18
49	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. *Journal of Thoracic Oncology*, **2017**, 12, 1015-1020	8.9	16
48	Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. *Annals of Thoracic Surgery*, **2021**, 111, 269-276	2.7	16
47	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. *Lung Cancer*, **2018**, 125, 115-120	5.9	16
46	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. *Molecular Oncology*, **2020**, 14, 1947-1965	7.9	14
45	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. *Clinical Cancer Research*, **2016**, 22, 3663-71	12.9	11
44	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. *Lung Cancer*, **2017**, 112, 57-61	5.9	11
43	Recent evidence, advances, and current practices in surgical treatment of lung cancer. *Respiratory Investigation*, **2014**, 52, 322-9	3.4	11
42	Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers. *Clinical Lung Cancer*, **2012**, 13, 488-93	4.9	11
41	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. *PLoS ONE*, **2016**, 11, e0154186	3.7	11
40	CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. *Lung Cancer*, **2014**, 85, 147-51	5.9	10
39	Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. *PLoS ONE*, **2015**, 10, e0123901	3.7	10
38	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. *PLoS ONE*, **2017**, 12, e0172209	3.7	10
37	Emerging oncogenic fusions other than , , , and in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. *Translational Lung Cancer Research*, **2020**, 9, 2618-2628	4.4	10
36	Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. *Expert Opinion on Emerging Drugs*, **2020**, 25, 229-249	3.7	9
35	Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case. *Thoracic Cancer*, **2015**, 6, 97-100	3.2	8
34	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. *Journal of Thoracic Oncology*, **2016**, 11, 1711-7	8.9	8

33	Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval. *Lung Cancer*, **2013**, 80, 99-101	5.9	7
32	Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. *BioMed Research International*, **2014**, 2014, 645681	3	7
31	Analysis of ERBB4 mutations and expression in japanese patients with lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 1859-61	8.9	7
30	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. *BioMed Research International*, **2017**, 2017, 7694202	3	6
29	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. **2013**,		6
28	Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance. *Thoracic Cancer*, **2021**, 12, 1511-1516	3.2	6
27	Lung Cancer with exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. *Lung Cancer: Targets and Therapy*, **2021**, 12, 35-50	2.9	6
26	Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. *Translational Lung Cancer Research*, **2019**, 8, 938-950	4.4	6
25	Prognostic impact of pleural lavage cytology in patients with primary lung cancer. *Lung Cancer*, **2016**, 102, 60-64	5.9	5
24	Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. *Cancer Research*, **2016**, 76, 3109-10	10.1	5
23	Prognostic value of plasma fibrinogen and D-dimer levels in patients with surgically resected non-small cell lung cancer. *Surgery Today*, **2020**, 50, 1427-1433	3	4
22	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts **2012**, 3, 438-43		4
21	Activity and mechanism of acquired resistance to tarloxotinib in mutant lung cancer: an study. *Translational Lung Cancer Research*, **2021**, 10, 3659-3670	4.4	4
20	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. *Clinical Lung Cancer*, **2018**, 19, 450-456	4.9	3
19	Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe. *Thoracic Cancer*, **2015**, 6, 672-7	3.2	3
18	Development of personalized treatments in lung cancer: focusing on the mutations and beyond. *Lung Cancer: Targets and Therapy*, **2013**, 4, 43-53	2.9	3
17	Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer. *Anticancer Research*, **2016**, 36, 6319-6326	2.3	3
16	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. *Lung Cancer*, **2020**, 148, 100-104	5.9	3

15	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations. *Cells*, **2021**, 10,	7.9	3
14	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. *Biomolecules*, **2019**, 9,	5.9	2
13	Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection. *Thoracic Cancer*, **2015**, 6, 655-8	3.2	2
12	Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged sword. *Molecular Cancer Research*, **2013**, 11, 1125-8	6.6	2
11	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. *Lung Cancer*, **2021**, 154, 84-91	5.9	2
10	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with Mutations. *Cells*, **2021**, 10,	7.9	2
9	DNA shedding in non-small-cell lung cancer: useful to assess?. *Lancet Respiratory Medicine,the*, **2018** , 6, 77-78	35.1	1
8	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. *Surgical Case Reports*, **2019**, 5, 105	0.8	1
7	Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.. *Cancer Science*, **2022**,	6.9	1
6	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. *Clinical Lung Cancer*, **2021**, 22, e141-e145	4.9	1
5	A case of anterior mediastinal malignant lymphoma complicated by lung adenocarcinoma. *The Journal of the Japanese Association for Chest Surgery*, **2015**, 29, 78-83	0	
4	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. *Lung Cancer*, **2021**, 162, 79-85	5.9	
3	The History and Current State of EGFR-TKIs. *Japanese Journal of Lung Cancer*, **2017**, 57, 69-74	0.1	
2	Evaluation of CD73 in lung cancer.. *Journal of Clinical Oncology*, **2017**, 35, e14525-e14525	2.2	
1	Abstract IA5: Genetic and genomic difference in lung cancer based on ethnicity. *Clinical Cancer Research*, **2012**, 18, IA5-IA5	12.9	